A33抗原表达调控机制及其抗体导向肿瘤放射免疫治疗  

Mechanism of A33' Tissue-Specific Expression and A33-Induced Radioimmunotherapy

作　　者：张勇[1] 王振宁[2] 

机构地区：[1]中国医科大学附属第一医院肿瘤外科,沈阳市110001 [2]中国医科大学医学基因组教研室,沈阳市110001

出　　处：《医学分子生物学杂志》2006年第3期231-233,244,共4页Journal of Medical Molecular Biology

基　　金：国家自然科学基金(No.30300342)~~

摘　　要：人肠上皮细胞表面抗原A33是一种在人胃肠道上皮细胞特异性表达的跨膜糖蛋白,在95%以上的大肠癌、63%的胃癌和50%的胰腺癌中表达,而在其它组织或其它肿瘤细胞中鲜有表达。近年来就A33的组织特异性表达模式进行了深入的研究,揭示了与A33的特异性表达相关的特异性启动子和组织特异性转录因子(GKLF、CDX1)。A33抗体导向下的直肠癌放射免疫治疗已成为单克隆抗体(monoc lonal an-tibody,MCAB)导向治疗研究领域的热点,且已经进入Ⅰ期放射免疫治疗临床实验。The human intestine tissue specific antigen A33 is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. It is expressed in more than 95% of human co- lon cancers, 63% of gastric cancers and 50% of pancreatic cancers, and it has not been found to express in other tissues or cancers. Over the past years, a lot of work has been done on the tissuespecific expression profile, and scientists have identified the promotor and transcription factor （GKLF, CDX1 ） that are associated with specific expression of A33. Advances have been made in the research of monolclonal antibodies for radioimmunotherapy and now the study is in the phase Ⅰ trial in patients with advanced colorectal carcinoma.

关 键 词：A33抗原 跨膜糖蛋白 组织特异性表达 放射免疫治疗 肿瘤 

分 类 号：Q786[生物学—分子生物学]